How a CRISPR, gene-editing technology, patent ruling could move stocks
Event Driven Takeaways
• The Federal Circuit will likely rule in 2018 on Berkeley’s appeal of the US Patent Office’s interference decision in favor of the Broad Institute. Berkeley’s licensees are Intellia (NTLA) and CRISPR Therapeutics (CRSP). Broad’s licensee is Editas Medicine (EDIT).
• The USPTO ruled on Feb. 15 that both Berkeley and the Broad Institute have different inventions and thus both parties are eligible for patents. Licensees of the related patents’ stock prices responded accordingly to the interference decision on Feb. 15.
• The USPTO indicated that the Berkeley application’s mention of the use of CRISPR (gene-editing) technology in eukaryotic cells (i.e., human), among several other cell-types, does not preclude the Broad Institute’s eligibility for a patent for their more developed use of CRISPR technology in eukaryotic cells.
• A win for Berkeley could benefit Berkeley’s licensees: NTLA and CRSP.
• A win for the Broad Institute could benefit Broad’s licensee: EDIT.
Originally Published at: How a CRISPR, gene-editing technology, patent ruling could move stocks